Welcome to our dedicated page for Nextcure SEC filings (Ticker: NXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NextCure, Inc. (NASDAQ: NXTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on targeted therapies, including antibody-drug conjugates for cancer, NextCure uses its SEC filings to report material agreements, financing transactions, corporate actions and financial results.
Through Forms 8-K, NextCure reports events such as private placements of common stock and pre-funded warrants, reverse stock split approvals and implementation, strategic collaborations, executive changes and Annual Meeting voting results. For example, the company has filed 8-Ks describing a securities purchase agreement for a private placement that raised approximately $21.5 million in gross proceeds, the effectuation of a one-for-twelve reverse stock split, and the outcome of stockholder votes on director elections and other proposals.
Periodic reports such as 10-K annual reports and 10-Q quarterly reports (not reproduced here but referenced in the company’s press releases) typically include detailed discussions of NextCure’s pipeline, risk factors, research and development expenses, general and administrative costs and net losses. The company’s forward-looking statement and risk disclosures reference its limited operating history, lack of approved products, need for additional financing and clinical development uncertainties.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key terms, highlight important sections and help interpret complex legal and financial language. Real-time updates from EDGAR ensure that new NextCure filings appear promptly, including current reports on material events, equity issuances and corporate governance matters.
Investors can also use this page to track information relevant to capital structure and shareholder rights, such as reverse stock split details, amendments to the certificate of incorporation and unregistered sales of equity securities. Together, these filings offer a structured view of how NextCure manages its clinical-stage operations, finances its programs and complies with public company reporting requirements.
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on antibody-drug conjugates to treat cancers that do not respond to current therapies. Its two lead candidates are SIM0505, a CDH6-targeted ADC licensed from Zaiming, and LNCB74, a B7-H4-targeted ADC co-developed with LigaChem.
SIM0505 and LNCB74 are both in Phase 1 trials, with early data updates planned in 2026. NextCure restructured operations in March 2024, pausing internal manufacturing and reducing its workforce to align with this focused pipeline. The company reported a net loss of $55.8 million in 2025, an accumulated deficit of $436.0 million, a non‑affiliate market value of about $12.6 million as of mid‑2025, and states it will need substantial additional capital. It holds an intellectual property portfolio expected to provide patent protection for LNCB74 and SIM0505 into 2039 and 2044, respectively.
NextCure reported full year 2025 results and highlighted progress on its antibody-drug conjugate pipeline. The company is preparing to present Phase 1 dose escalation data for SIM0505 in Q2 2026 and plans to begin enrolling platinum-resistant ovarian cancer patients into a Phase 1 dose optimization study, while doubling U.S. trial sites and expanding into additional countries.
For the year ended December 31, 2025, research and development expenses were 44,923 (in thousands) and general and administrative expenses were 12,693 (in thousands), with no restructuring and asset impairment charges compared to 2,542 (in thousands) in 2024. Net loss was 55,844 (in thousands), or 19.65 per basic and diluted share, versus 23.88 in 2024 (restated for a reverse stock split. Cash, cash equivalents, and marketable securities were 41,818 (in thousands) as of December 31, 2025, down from 68,621 (in thousands) a year earlier, and total stockholders’ equity declined to 34,943 (in thousands) from 65,472 (in thousands).
NextCure, Inc. major shareholder Sofinnova Venture Partners IX, L.P. filed Amendment No. 2 to its Schedule 13D reporting beneficial ownership of 222,654 shares of common stock, equal to 7.1% of the company. This percentage is based on 3,122,143 shares outstanding as of December 19, 2025.
The amendment explains that the ownership percentage declined by at least one percentage point due to dilution from NextCure’s additional sales of common stock reported in a recent prospectus supplement. Sofinnova, its general partner Sofinnova Management IX, L.L.C., and managing member Dr. James I. Healy hold the position for investment purposes and may buy, sell, or distribute shares over time depending on market conditions and their evaluation of NextCure, but report no transactions in the last 60 days.
Ikarian Capital, LLC and Neil Shahrestani reported beneficial ownership of 363,035 shares of NextCure, Inc. common stock, representing 9.99% of the class. The position is held through Ikarian Healthcare Master Fund, L.P. and certain separate managed accounts advised by Ikarian Capital.
The total includes 124,732 shares that may be acquired within 60 days via warrants, which are subject to a 9.99% beneficial ownership cap on exercise. The ownership is reported on a passive basis and the securities are stated as acquired and held in the ordinary course of business.
Squadron Master Fund LP and related parties report a significant stake in NextCure, Inc. common stock. They beneficially own 271,127 shares, including 236,966 shares of common stock and 34,161 shares issuable upon exercise of warrants. This position represents approximately 9.99% of NextCure’s common stock, based on 2,679,822 shares outstanding as of October 31, 2025 plus the warrant shares. The securities are held in the ordinary course of business and are not reported as being acquired to change or influence control of NextCure.
Pfizer Inc. and its affiliate Pfizer Ventures (US) LLC have updated their ownership disclosure for NextCure, Inc. common stock in an amended Schedule 13G. Pfizer reports beneficial ownership of 157,646 shares, representing 3.0% of the common stock, with 26,537 shares under sole voting and dispositive power and 131,109 shares under shared voting and dispositive power. Pfizer Ventures (US) LLC reports beneficial ownership of 131,109 shares, or 2.5% of the class, all with shared voting and dispositive power. These percentages are based on 5,203,290 shares outstanding as reported in NextCure’s final prospectus, which includes 1,815,049 shares issuable upon exercise of pre-funded warrants. The reporting persons certify that the securities are held without the purpose or effect of changing or influencing control of NextCure.
SilverArc Capital Management, LLC and its sole member Devesh Gandhi report beneficial ownership of 176,057 shares of NextCure, Inc. Class A common stock, representing 5.02% of the class as of 12/31/2025. All voting and dispositive power over these shares is shared, with no sole authority reported.
SilverArc is an SEC-registered investment adviser, and the shares are held for various advisory clients, who have the right to receive dividends and sale proceeds. Within this total, SilverArc Capital Alpha Fund I, L.P. is attributed 6,162 shares (about 0.18%), and SilverArc Capital Alpha Fund II, L.P. is attributed 169,895 shares (about 4.85%). The filing states the position is held in the ordinary course of business and not for the purpose of influencing control of NextCure.
NextCure, Inc. reported that its Sr VP and General Counsel, Kevin G. Shaw, received an employee stock option grant. On January 30, 2026, he was awarded an option to buy 8,270 shares of common stock at an exercise price of $10.85 per share.
According to the vesting schedule, one fourth of the option vests on January 30, 2027, and the remaining three fourths vest in 36 monthly installments beginning February 28, 2027. Following this grant, he beneficially holds 8,270 stock options directly.
NextCure, Inc. reported that its Chief Medical Officer, Udayan Guha, received an employee stock option grant on January 30, 2026. The option covers 14,670 shares of common stock at an exercise price of $10.85 per share and is held directly.
One quarter of the option vests on January 30, 2027, with the remaining three quarters vesting in 36 monthly installments starting February 28, 2027. The option expires on January 29, 2036 if not exercised.
NextCure, Inc. reported that Senior Vice President of Development and Manufacturing Sourav K. Kundu received an employee stock option grant. On January 30, 2026, he was awarded options to buy 8,270 shares of common stock at an exercise price of $10.85 per share.
One fourth of the option vests on January 30, 2027, with the remaining portion vesting in 36 monthly installments beginning February 28, 2027. Following this grant, Kundu beneficially owns 8,270 stock options, all held directly.